Oxailis, a spin-out from the University of Oxford, is set to commercialise a groundbreaking AI-based decision-support platform that enables non-invasive, quantitative assessment of tissue perfusion using standard 3D ultrasound systems. This is the first fully validated, automated solution for vascular function analysis across any organ using existing ultrasound hardware, offering a scalable, low-cost alternative to traditional contrast-based methods.
Developed by leading clinician-scientists and validated in over 7,500 patients, Oxailis’s technology delivers precise disease detection where perfusion is a critical biomarker. Initially proven in obstetrics, the OxNNet Toolkit is now being extended to high-impact areas including prostate and ovarian cancer, and nephrology, each marked by significant diagnostic gaps, cost pressures, and clinical uncertainty. Together, these markets represent a global serviceable opportunity exceeding $1 billion.
Oxailis holds exclusive patents covering perfusion quantification across all organs, positioning the company as a category-defining leader in ultrasound-based diagnostics.

Oxailis Ltd

Org chart

Teams

Offices

Oxailis Ltd

Org chart

Teams

Offices

Related companies